SPR and HDX-MS–Based Screening of AI Antibodies.
Advancing AI-Designed Antibodies with SPR and HDX-MS Screening.
In silico and artificial intelligence-developed antibodies and biologics are rapidly emerging, leveraging vast libraries and machine learning to computationally design molecules, simulate antibody affinity, specificity, structural modeling, and predict therapeutic potential.
In vitro validation is essential to de-risking and confidently advancing AI-designed antibodies, and surface plasmon resonance (SPR) and hydrogen-deuterium exchange mass spectrometry (HDX-MS) strike the ideal balance of throughput and thoroughness. Assays like ELISA or BLI often miss key details or return false negatives, peptide scanning overlooks non-linear epitopes, and crystallography is too slow. SPR instead delivers real-time kinetics, on/off-rates and affinities, for ranking candidates, while HDX-MS pinpoints epitope and paratope interactions to confirm predicted binding modes.
Together, they not only validate antibody-antigen interactions with unmatched accuracy but also feed critical information back into AI models, refining predictions and driving smarter, faster therapeutic development.
Services for AI Antibody Design & Development.
We support AI discovery and development companies through every stage of antibody validation and characterization, ensuring the best candidates advance with confidence.
Antibody Sequencing & Discovery Services.
SPR Screening
Validate AI-designed antibodies with real-time kinetics. SPR measures on/off rates and affinities, ranking candidates by binding quality, not just presence.
Explore SPR Services
HDX-MS Epitope Screening
Reveal where and how antibodies bind with high-resolution HDX-MS. Confirm predicted binding modes of AI-designed candidates with structural precision.
Advanced Characterization
Ensure your antibodies are fit for development. We provide detailed PTM and glycan analysis to assess stability, integrity, and manufacturability.
Explore Antibody Characterization Services
Antibody Discovery
Hedge your bets with REpAb® polyclonal sequencing, discover naturally selected antibodies directly from the immune response.
Explore Antibody Discovery Services
“The protein sequence allowed us to control the antibody, affinity maturation, and do large production. Being able to produce 20mg of Ab is big advantage.”
Talk to Our Scientists.
We Have Sequenced 10,000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics